Skip to content

A Detailed Look At What Patients Experience In Medullary Thyroid Cancer Clinical Study

Analyzing the Patterns of Patient Engagement and Trends in Participation Observed in Medullary Thyroid Cancer Clinical Trials

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06079723
Enrollment
500
Registered
2023-10-12
Start date
2024-11-30
Completion date
2026-11-30
Last updated
2023-10-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Medullary Thyroid Cancer

Keywords

Medullary Thyroid Cancer

Brief summary

Clinical studies, with a distinct emphasis on medullary thyroid cancer, play a pivotal role in evaluating the safety and effectiveness of novel treatments for this condition. These trials serve as essential tools to determine whether new medications surpass conventional therapies, providing substantial evidence to endorse their broader adoption. The primary objective is to meticulously examine trial completion rates and voluntary withdrawals within this specific patient group. By actively participating in this observational study plays a critical role in pushing medical knowledge forward and advancing care for individuals suffering from the medullary thyroid cancer.

Interventions

None listed

Sponsors

Power Life Sciences Inc.
Lead SponsorINDUSTRY

Study design

Observational model
CASE_CROSSOVER
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Confirmed diagnosis of medullary thyroid cancer * Aged ≥ 18 years old and ability to provide written informed consent obtained prior to participation in the study and any related procedures being performed * No serious medical or psychiatric illness likely to interfere with participation in this clinical study.

Exclusion criteria

* Is pregnant, breastfeeding or expecting to conceive within the projected duration of the study * Any serious and/or unstable pre-existing medical disorders * Patients who are currently receiving any other investigational drug.

Design outcomes

Primary

MeasureTime frame
Number of medullary thyroid cancer patients who decide to enroll in a clinical trial3 months
Rate of medullary thyroid cancer patients who remain in clinical trial to trial completion12 months

Countries

United States

Contacts

Primary ContactMichael B Gill
bask@withpower.com(415) 900-4227

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026